1 / 7

Developing Strategy for Next Generation of Antibody - Drug Conjugates

Comprised of a recombination monoclonal antibody and cytotoxic payloads through a linker, antibody drug conjugate (ADC) not only has highly cytotoxic antitumor effect of small molecule drugs, but also combines the high selectivity, stability and favorable pharmacokinetic characteristics of mAb.<br>

bellasmith123
Download Presentation

Developing Strategy for Next Generation of Antibody - Drug Conjugates

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Developing Strategy for Next Generation of Antibody - Drug Conjugates https://www.creative-biolabs.com/adc

  2. Antibody - Drug Conjugates What is ADC? Comprised of a recombination monoclonal antibody and cytotoxic payloads through a linker, antibody drug conjugate (ADC) not only has highly cytotoxic antitumor effect of small molecule drugs, but also combines the high selectivity, stability and favorable pharmacokinetic characteristics of mAb.

  3. The target antigen should be present on the cell surface so that the circulating mAb can enter. The target antigen should be the internal antigen, so that ADC is transferred to the cell after the combination and the cytotoxic agent can play its role. An ideal target antigen is supposed to have high expression level in tumors, with little or no expression in normal tissue, or at least the expression is limited to a given tissue type, in order to reduce the toxicity of ADC target toxicity and lead to an acceptable treatment index. Several factors need to be considered in antigen selection.

  4. ADC ADC, currently in clinical trials, is mostly targeted to DNA or microtubules, and has been optimized efficiently. Due to the limited number of antigens on the tumor cell surface and the low ratio of ADC turning into tumor cells, it may fail of the merger of cytotoxic drugs clinical. Auristatin and statin are the most commonly used ADC payloads by inhibiting the assembly of microtubules. Other using payloads usually are based on PBD, tubulysin, doxycycline, adrenaline, and so on. In fact, due to the intense competition, an increasing number of ADC in the early clinical trial study did not disclose the chemical structure of monoclonal antibody, payloads and ADC linkers.

  5. Achieving the enhancement and limitation of the bypass effect by the ability to cross the biofilm's linker and drug metabolites. The increase of solubility and reduction of MDR of polarity linker Conditional drug releases in the cytoplasm of target cells (cleavable and non-cleavable linkers) In order to enhance the solubility of ADC and conjugate DAR , a couple of strategies are as follows.

  6. GET IN TOUCH CONTACT US Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, preclinical evaluations, cGMP manufacturing, to clinical trails. Creative Biolabs 45-1 Ramsey Road, Shirley, NY 11967, USA Email: marketing@creative-biolabs.com

  7. THANKS FOR WATCHING

More Related